Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: WX-671|DRUG: placebo
Sponsor: Heidelberg Pharma AG
Collaborators: U.S. Army Medical Research and Development Command